Compare VYNE & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYNE | VTGN |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 24.1M |
| IPO Year | 2017 | 2014 |
| Metric | VYNE | VTGN |
|---|---|---|
| Price | $0.64 | $0.63 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 92.5K | ★ 619.3K |
| Earning Date | 05-08-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $0.43 |
| 52 Week High | $1.96 | $5.14 |
| Indicator | VYNE | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.94 | 56.46 |
| Support Level | $0.56 | $0.56 |
| Resistance Level | $0.75 | $0.66 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 85.05 | 79.11 |
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.